Toh hua yun ki Vivimed Labs ko CBI (Central Bureau of Investigation) ki Bengaluru branch se ek notice mila hai. Yeh notice 27 January 2026 ka hai, aur unko 29 January 2026 ko mila. Pata hai kis wajah se? Seedha State Bank of India (SBI) ne Hyderabad waali branch se complaint ki thi, kuch financial irregularities ke mamle mein.
Aur baat yahi nahi ruki, company ke financials ko lekar aur bhi badi khabar hai. Jo SBI ka pura debt tha na, woh ab Rare Asset Reconstruction Ltd. (Rare ARC) ne acquire kar liya hai. Iska matlab hai ki ab jo bhi paisa SBI ko dena tha, woh Rare ARC ko Vivimed Labs se recover karna padega, interest aur charges ke saath.
Ab ye sab dekh kar lag raha hai ki company financial problems mein kaafi phansi hui hai. Ek taraf CBI investigation chal rahi hai, doosri taraf debt transfer ho gaya. Isse naye funding milna, suppliers ke saath deal karna, aur company ke roz ke kaam-kaaj chalana, sab mushkil ho sakta hai.
Kya Risks Hain?
- Legal Issues: CBI investigation ka result negative aaya toh company par badi legal action ho sakti hai aur company ki reputation ko bhi nuksan pahunchega.
- Financial Stress: Debt Rare ARC ko transfer hone ka matlab hai ki company pehle se hi financial pressure mein hai. Ab Rare ARC pressure banayegi paisa vasool karne ka, jiske liye company ko assets bechna pad sakta hai.
- Operations Par Asar: Investors dekhenge ki is sab ka company ke daily operations, jaise manufacturing ya business development par kitna asar padta hai.
Aage Kya Ho Sakta Hai?
Investors ko CBI investigation par nazar rakhni hogi aur Rare ARC ke next steps ka intezaar karna hoga. Dekhna hoga ki company is mushkil situation se kaise nikal paati hai.